Skip to main content
SpringerLink
Log in

Natalizumab cost effective versus fingolimod for RRMS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. National Health Service

  2. 2016 British pounds

Reference

  • Herring W, et al. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease- modifying therapies in relapsing-remitting multiple sclerosis (RRMS) in Scotland. 70th Annual Meeting of the American Academy of Neurology : (plus poster) abstr. 364, 21 Apr 2018. Available from: URL: https://submissions.mirasmart.com/AAN2018/itinerary/SearchHome.asp

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Natalizumab cost effective versus fingolimod for RRMS. PharmacoEcon Outcomes News 804, 21 (2018). https://doi.org/10.1007/s40274-018-4985-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4985-0

Search

Navigation